The Unlikely Buddha

Pancreatic cancer is one of the deadliest forms of cancer, with a five-year survival rate of less than 13%. Its aggressive nature, late-stage diagnosis, and resistance to traditional treatments have made it a formidable challenge for researchers and clinicians alike. However, a groundbreaking approach spearheaded by Memorial Sloan Kettering Cancer Center (MSKCC) is offering new hope. Harnessing the power of mRNA technology—best known for its role in COVID-19 vaccines—scientists are developing personalized mRNA vaccines to treat pancreatic cancer. While this approach currently focuses on treating patients who already have the disease, it also lays the groundwork for a future where preventative vaccines could stop pancreatic cancer before it begins. Why the Immune System Struggles with Cancer The human immune system is a powerful defense mechanism designed to protect the body from harmful invaders, such as bacteria, viruses, and other pathogens. It does this by recognizi...